1. Home
  2. ENVB vs PTIX Comparison

ENVB vs PTIX Comparison

Compare ENVB & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENVB
  • PTIX
  • Stock Information
  • Founded
  • ENVB 1994
  • PTIX 1994
  • Country
  • ENVB United States
  • PTIX United States
  • Employees
  • ENVB N/A
  • PTIX N/A
  • Industry
  • ENVB Biotechnology: Pharmaceutical Preparations
  • PTIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENVB Health Care
  • PTIX Health Care
  • Exchange
  • ENVB Nasdaq
  • PTIX Nasdaq
  • Market Cap
  • ENVB 3.0M
  • PTIX 2.7M
  • IPO Year
  • ENVB N/A
  • PTIX 2016
  • Fundamental
  • Price
  • ENVB $0.97
  • PTIX $3.22
  • Analyst Decision
  • ENVB Strong Buy
  • PTIX
  • Analyst Count
  • ENVB 1
  • PTIX 0
  • Target Price
  • ENVB $10.00
  • PTIX N/A
  • AVG Volume (30 Days)
  • ENVB 325.7K
  • PTIX 8.3M
  • Earning Date
  • ENVB 08-14-2025
  • PTIX 09-10-2025
  • Dividend Yield
  • ENVB N/A
  • PTIX N/A
  • EPS Growth
  • ENVB N/A
  • PTIX N/A
  • EPS
  • ENVB N/A
  • PTIX N/A
  • Revenue
  • ENVB N/A
  • PTIX N/A
  • Revenue This Year
  • ENVB N/A
  • PTIX N/A
  • Revenue Next Year
  • ENVB N/A
  • PTIX N/A
  • P/E Ratio
  • ENVB N/A
  • PTIX N/A
  • Revenue Growth
  • ENVB N/A
  • PTIX N/A
  • 52 Week Low
  • ENVB $0.85
  • PTIX $2.25
  • 52 Week High
  • ENVB $8.33
  • PTIX $15.54
  • Technical
  • Relative Strength Index (RSI)
  • ENVB 40.51
  • PTIX 49.37
  • Support Level
  • ENVB $0.85
  • PTIX $2.79
  • Resistance Level
  • ENVB $1.06
  • PTIX $3.39
  • Average True Range (ATR)
  • ENVB 0.10
  • PTIX 0.36
  • MACD
  • ENVB -0.02
  • PTIX -0.04
  • Stochastic Oscillator
  • ENVB 19.34
  • PTIX 19.58

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: